PATH vs SKYE
Uipath Inc (PATH) versus Skye Bioscience, Inc. Common Stock (SKYE) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Skye Bioscience, Inc. Common Stock (SKYE) is a biotechnology company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
SKYE does not have a complete income-statement cache yet.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. SKYE currently screens at market cap $25.0M.
Not investment advice. Open the PATH and SKYE stock pages for the full models.
Not investment advice.